Drugs / BSB-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06704152 | Feb 2025 → Feb 2029 expected | acute myeloid leukemia, adult acute lymphoblastic leukemia, myelodysplastic syndrome | BlueSphere Bio, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | BlueSphere Bio, Inc | Regulatory BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients bluespherebio.com ↗
the Food and Drug Administration (FDA) has cleared BlueSphere’s Investigational New Drug application (IND) for a Phase 1/2a trial (TCX-101) of its first-in-human (BSB-1001) product candidate |
| 2022-11-10 | BlueSphere Bio, Inc | Results BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting bluespherebio.com ↗
Data supports BSB-1001 as a potential treatment to improve outcomes for patients with acute myeloid leukemia (AML) receiving a hematopoietic stem cell transplantation (HSCT) |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | BlueSphere Bio, Inc | BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients bluespherebio.com ↗ |
| 2022-11-10 | BlueSphere Bio, Inc | BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting bluespherebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSB-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06704152 ↗ |
| Modality | Cell therapy | “new type of cellular therapy” NCT06704152 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT06704152 ↗ |